Unusual suspect for antipsychotic-induced diabetes

Drug Discovery Today

Volumn 10, Issue 20, 2005, Pages 1338-

  O'Neill, Michael F ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; MUSCARINIC M3 RECEPTOR; MUSCARINIC M3 RECEPTOR ANTAGONIST; NEUROHORMONE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE; ZIPRASIDONE;

BINDING AFFINITY; BODY WEIGHT DISORDER; DIABETES MELLITUS; ENDOCRINE DISEASE; HUMAN; LAW SUIT; MOTOR DYSFUNCTION; NOTE; PARKINSON DISEASE; SCHIZOPHRENIA; WEIGHT GAIN;

EID: 27144515322     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(05)03630-5     Document Type: Short Survey

References (2)

1. Silvestre J.S., Prous J. Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes Methods Find. Exp. Clin. Pharmacol. 27 2005 289 304
2. Johnson D.E. Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets: role of muscarinic antagonism in antipsychotic-induced diabetes and hyperglycemia Diabetes 54 2005 1552 1558